# Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

> **NCT03145675** · PHASE4 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 378 (actual)

## Conditions studied

- Coronary Artery Disease
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Enoxaparin (Staged-dose PCI Group)
- **DRUG:** Enoxaparin (Single-dose PCI Group)
- **DRUG:** Enoxaparin (High-dose Group)
- **DRUG:** Enoxaparin (Standard-dose Group)

## Key facts

- **NCT ID:** NCT03145675
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-12
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-07-14
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145675, "Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03145675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*